Your browser doesn't support javascript.
loading
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Schlenk, R F; Stegelmann, F; Reiter, A; Jost, E; Gattermann, N; Hebart, H; Waller, C; Hochhaus, A; Platzbecker, U; Schafhausen, P; Blau, I W; Verbeek, W; Heidel, F H; Werner, M; Kreipe, H; Teleanu, V; Benner, A; Döhner, H; Grießhammer, M; Döhner, K.
Afiliación
  • Schlenk RF; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Stegelmann F; NCT Trial Center, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Reiter A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Jost E; Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
  • Gattermann N; Department of Internal Medicine IV, University Hospital Aachen, Aachen, Germany.
  • Hebart H; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
  • Waller C; Department of Hematology and Oncology, Stauferklinikum Mutlangen, Mutlangen, Germany.
  • Hochhaus A; Department of Internal Medicine I, University Hospital and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Platzbecker U; Internal Medicine II, Jena University Hospital, Jena, Germany.
  • Schafhausen P; Department of Internal Medicine I, University Hospital Dresden and GP Hematology and Oncology, Dresden, Germany.
  • Blau IW; Department of Internal Medicine II, University Hospital Hamburg, Hamburg, Germany.
  • Verbeek W; Department of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany.
  • Heidel FH; Center of Outpatient Hematology and Oncology, Bonn, Germany.
  • Werner M; Department of Hematology and Oncology, University Hospital Magdeburg, Magdeburg, Germany.
  • Kreipe H; Department of Pathology, University of Freiburg, Freiburg, Germany.
  • Teleanu V; Department of Pathology, Hannover Medical School, Hannover, Germany.
  • Benner A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Döhner H; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Grießhammer M; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Döhner K; Department of Oncology, Klinikum Minden, Minden, Germany.
Leukemia ; 31(4): 889-895, 2017 04.
Article en En | MEDLINE | ID: mdl-27774990
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Talidomida / Mielofibrosis Primaria / Factores Inmunológicos / Trastornos Mieloproliferativos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Talidomida / Mielofibrosis Primaria / Factores Inmunológicos / Trastornos Mieloproliferativos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article